Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer
Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer Summary Rechallenge with immune checkpoint inhibitors (ICIs) in advanced lung cancer patients who initially benefited but later progressed is a growing area of interest. Studies suggest that a subset of patients may experience renewed benefit from ICI re-exposure, particularly those with a prolonged…













